Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Checked against the public recordLast updated Aug 25, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Novartis Pharmaceuticals
- Interventions being studied
- Drug: dabrafenib; Drug: trametinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective. * In the opinion of the Investigator would benefit from continued treatment. Exclusion Criteria: * Patient has been previously permanently discontinued from study treatment in the parent protocol. * Patient's indication is commercially available and reimbursed in the local country. * Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Honor Health Research InstituteScottsdale, Arizona
- National Institute Of HealthBethesda, Maryland
- James Cancer Hospital and Solove Research Institute Ohio StateColumbus, Ohio
- Mary Crowley Cancer ResearchDallas, Texas
- Novartis Investigative SiteCaba, Buenos Aires
- Novartis Investigative SiteInnsbruck, Tyrol
- Novartis Investigative SiteBeijing
- Novartis Investigative SiteCopenhagen
- Novartis Investigative SiteLyon
- Novartis Investigative SiteNantes
- Novartis Investigative SiteParis
- Novartis Investigative SiteParis
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2026. Always confirm current availability with the study team.